TALLAHASSEE, FL--(Marketwire - Jul 25, 2012) -  Global Green, Inc. (OTCBB: [ GOGC ]) today announced that it is focused on the poultry vaccine market, a subsegment of the $5.4 billion veterinary vaccine market. The Company is factoring the industry's drivers into their corporate growth strategies. Salmogenics, Global Green's flagship product, is a patented, exclusively licensed Salmonella vaccine targeted to the growing poultry veterinary market. The Vaccine is currently in the final stage of the USDA approval process.

The global market for Veterinary Vaccines is forecast to reach $5.4 billion by the year 2015, according to Global Industry Analysts, Inc. 

The veterinary vaccine market includes many segments: companion animal vaccines (canine vaccines and feline vaccines) and livestock vaccines (porcine vaccines, bovine vaccines, poultry vaccines, ovine vaccines, equine vaccines) and other animal vaccines. Livestock vaccines represent the largest product group in the veterinary vaccines market, according to Global Industry Analysts, Inc. Currently, Global Green is focusing on the use of Salmogenics on a subsegment of livestock vaccines, poultry vaccines.

Key factors driving growth in this segment include the growing number of diseases in animals, increasing public awareness of the issue, and technological advancements in biotechnology research. Further, the ability of the vaccines to promote growth, develop immunity against diseases and lower the rate of mortality in the animals is driving sales of veterinary vaccines.

Salmogenics substantially reduces Salmonella in poultry, a significant protein source for much of the world's population. Per-capita consumption of chicken in the U.S. is increasing after three years of decline driven by the economic recession, reduced domestic availability due to exports and increased feed costs, according to the National Chicken Council.

"Global Green's growth strategies are focused on identifying market segments and geographic markets poised for strong growth," commented Dr. Mehran Ghazvini, Chairman and CEO.

According to the World Health Organization, which last compiled data in 2005, Salmonella in the U.S. accounts for 168,000 hospital visits, 15,000 hospitalizations, and 580 human deaths each year. Salmonella is a public health burden estimated to reach an annual cost of $3 billion. Poultry is a known to be a major global reservoir of the Salmonella bacteria.

Salmogenics fights multiple strains of Salmonella bacteria in poultry. The vaccine is unique in that it is injected directly into the egg, before the chick is hatched, improving the immune system, health and welfare of the chicken, and providing a healthier source of protein for humans in a cost effective manner.

Global Green, Inc. is a green pharmaceutical company committed to identifying technology platforms and commercializing products that contain natural organisms that are not genetically modified, utilizing pharmaceutical standards. Salmogenics, the Company's flagship product, was developed by Nutritional Health Institute Laboratories, LLC, a research affiliate and majority shareholder. The vaccine is currently in the final stage of the USDA approval process. For more information, visit [ www.globalgreeninc.org ].

Forward-Looking Statement
This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that such forward-looking statements involve risks and uncertainties, which include among others, the inherent uncertainties associated with smaller reporting companies, including without limitation, other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.